H M Klomp
Overview
Explore the profile of H M Klomp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joosten P, de Langen A, van der Noort V, Monkhorst K, Klomp H, Veenhof A, et al.
Lung Cancer
. 2021 Oct;
161:141-151.
PMID: 34600405
Objectives: Patients with advanced stage non-small cell lung cancer (NSCLC) are generally considered incurable. The mainstay of treatment for these patients is systemic therapy. The addition of local treatment, including...
2.
Kappers I, Vollebergh M, van Tinteren H, Korse C, Nieuwenhuis L, Bonfrer J, et al.
Ecancermedicalscience
. 2012 Jan;
4:178.
PMID: 22276032
Background: In patients with non-small cell lung cancer (NSCLC), a higher response rate can be achieved with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) when selection for therapy is guided...
3.
Van Schil P, Baas P, Gaafar R, Maat A, van de Pol M, Hasan B, et al.
Eur Respir J
. 2010 Jun;
36(6):1362-9.
PMID: 20525721
The European Organisation for Research and Treatment of Cancer (EORTC; protocol 08031) phase II trial investigated the feasibility of trimodality therapy consisting of induction chemotherapy followed by extrapleural pneumonectomy and...
4.
Geurts T, Klomp H, Burgers S, van Tinteren H, Roukema B, Balm A
J Laryngol Otol
. 2010 Jun;
124(12):1278-83.
PMID: 20519045
Background: This study aimed to evaluate a single institute's experience with resection of metachronous pulmonary malignancy in patients treated for squamous cell carcinoma of the head and neck. Methods: Sixty-three...
5.
Klomp H, Steyerberg E, Wittens C, van Urk H, Habbema J
Vasc Med
. 2009 Apr;
14(2):109-15.
PMID: 19366816
In a (negative) multicenter randomized trial on management for inoperable critical lower limb ischemia, comparing spinal cord stimulation and best medical treatment, a number of pre-defined factors were analyzed for...
6.
Klomp H, Steyerberg E, Habbema J, van Urk H
Ann Vasc Surg
. 2009 Jan;
23(3):355-63.
PMID: 19128928
The use of spinal cord stimulation (SCS) has been advocated for the management of ischemic pain and the prevention of amputations in patients with inoperable critical limb ischemia (CLI), although...
7.
van Sandick J, Kappers I, Baas P, Haas R, Klomp H
Ann Surg Oncol
. 2008 Apr;
15(6):1757-64.
PMID: 18398658
Background: A minority of patients with malignant pleural mesothelioma (MPM) are considered for surgery. To achieve a microscopically radical resection, combination with other treatment modalities is mandatory. The most effective...
8.
Kappers I, Belderbos J, Burgers J, van Zandwijk N, Groen H, Klomp H
Lung Cancer
. 2007 Oct;
59(3):385-90.
PMID: 17913281
The combination of radiotherapy and concurrent chemotherapy followed by surgery (trimodality treatment) is currently regarded as optimal treatment for non-small cell lung cancer of the superior sulcus (SST) or Pancoast...
9.
Spinal cord stimulation is not cost-effective for non-surgical management of critical limb ischaemia
Klomp H, Steyerberg E, van Urk H, Habbema J
Eur J Vasc Endovasc Surg
. 2006 Jan;
31(5):500-8.
PMID: 16388973
Objective: To quantify the costs of treatment in critical limb ischaemia (CLI) and to compare costs and effectiveness of two treatment strategies: spinal cord stimulation (SCS) and best medical treatment....
10.